Polybrominated diphenyl ethers (PBDEs) have been reported to possess endocrine-disrupting and tumour-promoting activity. However, the effects of long-term exposure to decabromodiphenyl ether (BDE209) on thyroid tumourigenesis of papillary thyroid carcinoma (PTC) and the underlying mechanisms remain poorly defined. In this study, functional assays in vitro and mouse models in vivo were used to evaluate the toxic effects of long-term exposure to environmental concentrations of BDE209 on the pathogenesis and progression of PTC. MTS, EdU and colony-forming assays confirmed the chronic toxicity of BDE209 on the proliferation of human normal follicular epithelial cell line (Nthy-ori 3-1) and PTC-derived cell lines (TPC-1 and BCPAP). Wound and Transwell assays showed that BDE209 exacerbated the aggressiveness of PTC cells. BDE209 significantly promoted cell proliferation during the S and G2/M phases of the cell cycle. Mechanistically, BDE209 altered the thyroid system by acting as a competitive inhibitor of thyroid receptor beta (TRß) expression and function, which was further proven by public databases and RNA-seq bioinformation analysis. Taken together, these results demonstrated that BDE209 has chronic toxicity and potential tumourigenic effects on the thyroid by inhibiting TRß.
Background: This study aims to investigate isocitrate dehydrogenase gene mutations in patients with the non-hereditary skeletal disorders of Ollier disease and Maffucci syndrome, particularly in the extraosseous tumours. Methods: A total of 16 tumours from three patients with Ollier disease and three patients with Maffucci syndrome were collected. Sanger sequencing was applied to determine the hotspot mutations of IDH1 and IDH2 genes in multiple neoplastic tissues. Results: A majority of the tumours displayed an IDH1 mutation (p.R132C in 11 tumours including the paediatric ovarian tumour from one patient with Ollier disease, 4 cutaneous haemangiomas from three patients with Maffucci syndrome, 5 enchondromas and 1 chondrosarcoma; p.R132H in 2 cartilaginous tumours from one patient). Conclusions: IDH1 mutations were demonstrated in multiple cartilaginous tumours and extraskeletal neoplasms in this case series. Specifically, identical IDH1 mutations were confirmed in the separate lesions of each patient. These results are in concordance with findings that have been reported. However, here, we additionally reported the first case of Ollier disease with an ovarian tumour, which harboured the identical IDH1 mutation with the corresponding cartilaginous tumour. We further provided evidence that IDH mutations are the potential genetic links among the multiple neoplastic lesions of Ollier disease and Maffucci syndrome.
30 January 2026 in Journal for ImmunoTherapy of Cancer
Background: Although immunotherapy has revolutionized cancer treatment, its efficacy in castration-resistant prostate cancer (CRPC) remains limited, largely due to an immunologically “cold” tumor microenvironment with scarce T-cell infiltration. Unraveling the molecular mechanisms underlying immune evasion and developing novel strategies to activate innate antitumor immunity are therefore critical to overcoming immunotherapy resistance in CRPC. Methods: Using bioinformatic approaches, we analyzed the protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1) expression and its correlation with immune cell infiltration and response to immune checkpoint blockade (ICB) in public databases. PKMYT1 protein expression was further evaluated via immunohistochemistry in a clinical cohort of prostate cancer (PCa) specimens. Mechanistic investigations were conducted in PCa cell lines and mouse models. The immunological impact of PKMYT1 inhibition was delineated using single-cell RNA sequencing, and the therapeutic efficacy of RP-6306, either as monotherapy or in combination with programmed death-ligand 1 (PD-L1) blockade, was evaluated in syngeneic mouse models. Results: PKMYT1 expression was significantly overexpressed in CRPC compared with primary PCa. High PKMYT1 expression correlated with a suppressed antitumor immunity and poor clinical response to ICB. Mechanistically, PKMYT1 inhibition activated the cyclic guanosine monophosphate-adenosine monophosphate adenosine synthase (cGAS)-stimulator of interferon genes (STING) pathway, potentiated both type I and II interferon signaling, and upregulated chemokines, including CCL5 and CXCL10. The selective PKMYT1 inhibitor, RP-6306, enhanced the efficacy of ICB in the presence of CD8 + T cells. Treatment with a PKMYT1 inhibitor alone or in combination with PD-L1 blockade significantly increased the infiltration of activated CD8 + T cells and induced significant tumor suppression in vivo. Conclusion: PKMYT1 is a pivotal dual regulator of tumor progression and immune evasion in CRPC. Our findings provide a compelling preclinical rationale for targeting PKMYT1 as a novel strategy to reprogram the tumor immune microenvironment and overcome resistance to immunotherapy.